Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics
illi News/10149943

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capabilities of a technology company with those of a biopharmaceutical company, the two companies hope to advance drug discovery and development, to more quickly deliver innovation to patients.

The strategic collaboration aims to optimize Tempus' AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale. Under the terms of the agreement, AstraZeneca will leverage Tempus' de-identified data and analytical tools across a broad range of capabilities. This collaboration combines Tempus' AI and machine learning capabilities for identifying novel insights with AstraZeneca's deep expertise in R&D to ultimately develop new therapeutic options for patients.

More on illi News

• DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
• CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
• Vinitaly International Academy welcomes Guido Berlucchi & C. SpA once again as Educational Supporter for its 33rd Certification Course
• Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
• 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus

"Artificial intelligence has the potential to advance precision medicine in ways that seemed unimaginable just a few short years ago," said Eric Lefkofsky, Founder and CEO of Tempus. "We look forward to working with AstraZeneca to apply AI-enabled solutions to advance its robust therapeutic pipeline in an effort to help patients live longer and healthier lives."

"Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence," said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. "We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline."

About Tempus

More on illi News

• BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
• NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
• Sci-Fi Author Don Viecelli Introduces Alien Times - Book 3, Retribution
• Poncho Tha Popstar: The West's Next King
• Physician-Turned-Patient Launches Advocacy Campaign to Spotlight Disability Insurance Barriers

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Erin Carron
erin.carron@tempus.com

---

Show All News | Report Violation